Zanamivir

Zanamivir
Clinical data
Pronunciation	/zəˈnæmɪvɪər/
Trade names	Relenza, others
AHFS/Drugs.com	Monograph
MedlinePlus	a699021
License data	US DailyMed: Zanamivir;
Pregnancy; category	AU: B1;
Routes of; administration	Inhalation, intravenous
ATC code	J05AH01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	2% (oral)
Protein binding	<10%
Metabolism	Negligible
Elimination half-life	2.5–5.1 hours
Excretion	Kidney
Identifiers
	IUPAC name (2R,3R,4S)-4-guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid;
CAS Number	139110-80-8 ;
PubChem CID	60855;
DrugBank	DB00558 ;
ChemSpider	54842 ;
UNII	L6O3XI777I;
KEGG	D00902 ;
ChEBI	CHEBI:50663 ;
ChEMBL	ChEMBL222813 ;
PDB ligand	ZMR (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID0023749 ;
ECHA InfoCard	100.218.632
Chemical and physical data
Formula	C12H20N4O7
Molar mass	332.313 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)C=1O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](/N=C(\N)N)C=1;
	InChI InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1 ; Key:ARAIBEBZBOPLMB-UFGQHTETSA-N ;
	(verify)

Zanamivir, sold under the brand name Relenza among others, is an anti-viral medication used to treat and prevent influenza caused by influenza A and influenza B viruses. It is a neuraminidase inhibitor and was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo Wellcome in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir is the first neuraminidase inhibitor commercially developed. It was developed by GlaxoSmithKline.